Viatris Inc.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript

VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.

Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November Raises 2026 Financial Guidance Midpoints for All Metrics …

Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

PITTSBURGH, Nov. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that on November 2, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 16, 2026, to shareholders of record as of the close of business on November 23, 2026.

VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.

The third-quarter 2026 earnings season is revealing a familiar healthcare divide: demand is holding up, but not every business is turning that demand into stronger profits. Laboratories are ordering more equipment, cancer testing continues to expand, and animal health innovation is attracting customers.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upo…

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSciences" or the "Company") (NASDAQ: PCRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Viatris Inc. (NASDAQ: VTRS) for $36.50 per share in cash, representing an aggregate equity value of $1.65 bi…